NASDAQ: LFWDLifeward Ltd Stock
$4.75-0.14 (-2.86%)
Updated Apr 24, 2024
LFWD Price
$4.75
Fair Value Price
N/A
Market Cap
$40.36M
52 Week Low
$3.90
52 Week High
$9.10
P/E
-1.83x
P/B
0.87x
P/S
3.35x
PEG
N/A
Dividend Yield
N/A
Revenue
$13.85M
Earnings
-$22.13M
Gross Margin
32.1%
Operating Margin
-159.85%
Profit Margin
-159.8%
Debt to Equity
0.36
Operating Cash Flow
-$21M
Beta
0.7
Next Earnings
May 9, 2024
Ex-Dividend
N/A
Next Dividend
N/A
LFWD Overview
ReWalk Robotics Ltd., a medical device company, designs, develops, and commercializes robotic exoskeletons for individuals with mobility impairments or other medical conditions in the United States, Europe, the Asia-Pacific, and Africa. The company offers ReWalk Personal and ReWalk Rehabilitation for spinal cord injuries and everyday use by paraplegic individuals at home and in communities; ReStore, a soft exo-suit intended for use in the rehabilitation of individuals with lower limb disability due to stroke in the clinical rehabilitation environment; and MyoCycle and MediTouch tutor movement biofeedback devices for use at home or in clinic. It markets and sells its products directly to third party payers; institutions, including rehabilitation centers; and individuals, as well as through third-party distributors. The company was formerly known as Argo Medical Technologies Ltd. ReWalk Robotics Ltd. was incorporated in 2001 and is headquartered in Yokneam Illit, Israel.
Zen Score
–
Industry Average (27)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how LFWD scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
LFWD is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
LFWD is good value based on its book value relative to its share price (0.87x), compared to the US Medical Devices industry average (3.73x)
P/B vs Industry Valuation
LFWD is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more LFWD due diligence checks available for Premium users.
Be the first to know about important LFWD news, forecast changes, insider trades & much more!
LFWD News
Valuation
LFWD fair value
Fair Value of LFWD stock based on Discounted Cash Flow (DCF)
Price
$4.75
Fair Value
-$4.90
Undervalued by
196.85%
LFWD is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
LFWD price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.83x
Industry
30.46x
Market
41.27x
LFWD price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.87x
Industry
3.73x
LFWD is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
LFWD's financial health
Profit margin
Revenue
$6.9M
Net Income
-$5.6M
Profit Margin
-81.9%
LFWD's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
LFWD's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$63.2M
Liabilities
$16.7M
Debt to equity
0.36
LFWD's short-term assets ($39.22M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
LFWD's short-term assets ($39.22M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
LFWD's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
LFWD's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$4.5M
Investing
-$79.0k
Financing
$0.0
LFWD's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
LFWD vs Medical Device Stocks
Lifeward Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.